Jay Bradner, NIBR president (Jeff Rumans)

No­var­tis is 'all in' on siR­NA, ink­ing a new col­lab­o­ra­tion with Al­ny­lam to de­vel­op al­ter­na­tive to liv­er trans­plants

Al­ny­lam was a few years ahead in the small in­ter­fer­ing RNA (siR­NA) space when No­var­tis jumped on the band­wag­on in ear­ly 2020, li­cens­ing the com­pa­ny’s cho­les­terol-low­er­ing drug Leqvio through its buy­out of The Med­i­cines Com­pa­ny. Less than a month af­ter se­cur­ing an ap­proval, the phar­ma gi­ant wants more where that came from.

No­var­tis is join­ing forces with Al­ny­lam once again for the dis­cov­ery and de­vel­op­ment of a re­gen­er­a­tive siR­NA-based ther­a­py to treat end-stage liv­er dis­ease, the com­pa­nies an­nounced on Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA